
ANIX Stock Forecast & Price Target
ANIX Analyst Ratings
Bulls say
Anixa Biosciences is positioned as an early-stage immuno-oncology platform with differentiated approaches in both cancer prevention and treatment, supported by their breast cancer vaccine and ovarian cancer CAR-T therapies. The recent update on their ovarian cancer CAR-T program at a major oncology conference solidifies their progress and enforces ongoing enrollment and investigator engagement. With promising top line revenue numbers for their CAR-T program, Anixa Biosciences shows potential for continued clinical advancement and investor interest.
Bears say
Anixa Biosciences is a biotechnology company with a negative outlook due to its limited financial resources and lack of significant partnerships or collaborations. The company's current reportable segments show a lack of diversification and dependence on its Cancer Vaccines and CAR-T Therapies segments, which have yet to show significant developments or successes in their treatments. This, along with the limited patent licensing activities and lack of revenue-generating products, make it a risky investment option.
This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
ANIX Analyst Forecast & Price Prediction
Start investing in ANIX
Order type
Buy in
Order amount
Est. shares
0 shares